ストックスクリーナーアプリを入手
473.79
1.50%
-7.21
アフターアワーズ：
473.02
-0.77
-0.16%
前日終値:
$481.00
開ける：
$483.9
24時間の取引高:
256.38K
Relative Volume:
0.79
時価総額：
$10.76B
収益：
-
当期純損益:
$-518.67M
株価収益率:
-18.86
EPS:
-25.12
ネットキャッシュフロー:
$-438.32M
1週間 パフォーマンス:
+2.24%
1か月 パフォーマンス:
-7.20%
6か月 パフォーマンス:
+31.97%
1年 パフォーマンス:
+39.28%
1日の値動き範囲:
$468.08
$484.25
1週間の範囲:
$463.53
$499.55
52週間の値動き範囲:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
名前
Madrigal Pharmaceuticals Inc
セクター
電話
404-380-9263
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
473.79 | 10.92B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-06 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-09-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-28 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-06-28 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2024-04-22 | 開始されました | BofA Securities | Underperform |
| 2024-03-15 | アップグレード | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 開始されました | Citigroup | Buy |
| 2024-02-26 | ダウングレード | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 繰り返されました | Oppenheimer | Outperform |
| 2022-12-19 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-19 | 繰り返されました | Piper Sandler | Overweight |
| 2022-12-19 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-11-24 | 再開されました | Evercore ISI | Outperform |
| 2020-11-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-05 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-01-30 | 開始されました | Canaccord Genuity | Buy |
| 2020-01-09 | アップグレード | UBS | Neutral → Buy |
| 2019-11-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-25 | 開始されました | Stifel | Hold |
| 2019-06-10 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-12-12 | 開始されました | B. Riley FBR | Neutral |
| 2018-11-19 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 開始されました | Citigroup | Buy |
| 2018-08-06 | ダウングレード | Goldman | Buy → Neutral |
| 2018-06-28 | 開始されました | Raymond James | Mkt Perform |
すべてを表示
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Madrigal expands its MASH pipeline via Ribo deal - The Pharma Letter
Madrigal expands MASH pipeline with siRNA therapies in $4.4 B deal - BioSpectrum Asia
Suzhou Ribo Life Science Signs Global siRNA Licensing Deal With Madrigal Pharma; Shares Rise 7% - marketscreener.com
Is Madrigal Pharmaceuticals Inc. in a long term uptrendJuly 2025 Retail & Trade Opportunity Analysis Reports - mfd.ru
Madrigal Continues Building Out MASH Pipeline With Ribo Life Science Deal - Citeline News & Insights
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH - Finviz
Madrigal builds in MASH with $4.4bn+ Ribo alliance - pharmaphorum
Madrigal Pharmaceuticals (MDGL) Secures $4.46B Licensing Deal wi - GuruFocus
Madrigal licenses six Ribo siRNA programs - BioWorld MedTech
Madrigal inks licensing deal for MASH drugs (MDGL:NASDAQ) - Seeking Alpha
Madrigal expands its MASH pipeline with exclusive global licensing agreement for six preclinical siRNA programs - marketscreener.com
Madrigal, China's Suzhou Ribo sign license deal for liver-disease programs - marketscreener.com
Madrigal turns to RNAi drugs from China to bolster MASH pipeline - Yahoo Finance
Madrigal, Suzhou Ribo in license deal for liver-disease programs - marketscreener.com
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals (MDGL) Secures Global License for siRNA Programs - GuruFocus
Madrigal Pharmaceuticals, Inc. announced an exclusive global licensing agreement to introduce six preclinical-stage siRNA (small interfering RNA) programs, aiming to significantly expand its research and development pipeline for metabolic dysfunction-asso - Bitget
Madrigal Pharmaceuticals Expands MASH Pipeline with Exclusive License for siRNA Programs - Quiver Quantitative
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs - GlobeNewswire
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by First National Trust Co - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals - Intellectia AI
Madrigal Grants Equity to New Hires as MASH Drug Momentum Builds - MyChesCo
Madrigal Sets Date to Reveal 2025 Results as Investors Watch Closely - MyChesCo
Aug Update: Is Madrigal Pharmaceuticals Inc stock good for income investorsRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Madrigal Equity Grants Signal Hiring Push And Undervalued Share Opportunity - Sahm
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule - marketscreener.com
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Commit To Buy Madrigal Pharmaceuticals At $350, Earn 14.6% Annualized Using Options - Nasdaq
Federated Hermes Inc. Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Does Madrigal Pharmaceuticals (MDGL) Offer Value After Recent Share Price Weakness - simplywall.st
Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth - Investing.com Canada
Madrigal Pharmaceuticals to report financial results on February 19 - Traders Union
18,291 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by WCM Investment Management LLC - MarketBeat
How (MDGL) Movements Inform Risk Allocation Models - Stock Traders Daily
Novo Set To Make MASH Move On Madrigal In EU With Kayshild - Citeline News & Insights
Madrigal Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Quiver Quantitative
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 - The Manila Times
Madrigal Pharmaceuticals to Release Fourth-Quarter and - GlobeNewswire
Madrigal Builds Commercial Bench With Equity Grants Around Rezdiffra Growth Story - Sahm
Madrigal Pharmaceuticals (MDGL) Price Target Increased by 10.39% to 562.78 - MSN
Pharma News: How does INNV perform in inflationary periods2025 Trading Recap & Weekly Stock Performance Updates - baoquankhu1.vn
Valuation Update: Will Madrigal Pharmaceuticals Inc outperform during market rallies2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Breakouts Watch: What are analysts price targets for Madrigal Pharmaceuticals IncCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Bull Bear: Is Madrigal Pharmaceuticals Inc stock a value trapIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
New York State Common Retirement Fund Grows Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche - TipRanks
Madrigal Pharmaceuticals Inc (MDGL) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):